Everolimus immunosuppression for renal protection, reduction of allograft vasculopathy and prevention of allograft rejection in de-novo heart transplant recipients: could we have it all?

Gude, Einar; Gullestad, Lars; Andreassen, Arne K

Gude, Einar; Gullestad, Lars; Andreassen, Arne K.

Affiliation

Gude E; aDepartment of Cardiology, Oslo University Hospital Rikshospitalet bCenter for Heart Failure Research cFaculty of Medicine, University of Oslo, Oslo, Norway.

Curr Opin Organ Transplant ; 22(3): 198-206, 2017 Jun.

Article in En | MEDLINE | ID: mdl-28463861

Subject(s)

Allografts/transplantation; Antineoplastic Agents/therapeutic use; Everolimus/therapeutic use; Graft Rejection/prevention & control; Heart Transplantation/methods; Immunosuppression Therapy/methods; Antineoplastic Agents/administration & dosage; Antineoplastic Agents/pharmacology; Everolimus/administration & dosage; Everolimus/pharmacology; Humans; Risk Factors

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Heart Transplantation / Immunosuppression Therapy / Allografts / Everolimus / Graft Rejection / Antineoplastic Agents Type of study: Etiology_studies / Guideline / Risk_factors_studies Limits: Humans Language: En Journal: Curr Opin Organ Transplant Year: 2017 Type: Article Affiliation country: Norway

Fulltext

XML

PubMed Links

Search on Google